24/7 Clients Support
| Brand Name | APRELIEVA 150MG |
| Composition | Fosaaprepitant Dimeglumine for Injection 150mg |
| Manufacture By | Allieva Pharma Private Limited |
| Form | Injection |
| Packing | Vial |
| Country Of Origin | India |
| Description | APRELIEVA 150 mg contains Fosaprepitant Dimeglumine, a neurokinin-1 (NK1) receptor antagonist. It is a prodrug of aprepitant and works by blocking substance P in the brain, thereby preventing chemotherapy-induced nausea and vomiting (CINV), especially delayed emesis. |
| Uses | Fosaprepitant is used for prevention of: 1. Chemotherapy-Induced Nausea and Vomiting (CINV) It is used in combination with: • A 5-HT3 receptor antagonist (e.g., ondansetron) • Dexamethasone |
| Side Effects | Common side effects: • Fatigue • Hiccups • Headache • Constipation or diarrhea Injection-site reactions: • Pain • Erythema • Phlebitis Serious side effects (rare): • Hypersensitivity reactions • Anaphylaxis Monitor for infusion-site reactions. |
| Dosage | Standard adult dose: • 150 mg IV single dose • Administered 30 minutes before chemotherapy on Day 1 Replaces 3-day oral aprepitant regimen. |